532523:BOM
Biocon Ltd
₹ 350,00
arrow_downward
-0,43%(-1,50) 1D
16 de out., 15:30:00 GMT+5:30 · INR
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para 532523…
Abrir
₹ 352,95
Alta
₹ 352,95
Baixa
₹ 348,10
Valor de mercado
568,79 bi
Volume médio
692,61 mil
Volume
668,34 mil
Dividendo
0,14%
Dividendo trimestral
₹ 0,13
Data de ex-dividendo
3 de jul. de 2026
Índice P/L
103,62
Alto — 52 sem
₹ 447,00
Baixo — 52 sem
₹ 337,95
LPA
₹ 3,38
Ações em circulação
600,00 mi
Nº de funcionários
16 mil
Abrir
₹ 352,95
Alta
₹ 352,95
Baixa
₹ 348,10
Valor de mercado
568,79 bi
Volume médio
692,61 mil
Volume
668,34 mil
Dividendo
0,14%
Dividendo trimestral
₹ 0,13
Data de ex-dividendo
3 de jul. de 2026
Índice P/L
103,62
Alto — 52 sem
₹ 447,00
Baixo — 52 sem
₹ 337,95
LPA
₹ 3,38
Ações em circulação
600,00 mi
Nº de funcionários
16 mil
Notícias
De fontes da web e parceiros de notícias
Dalal Street Investment Journal
·
há 2 dias
Biocon settles Genentech disputes, secures 2027 EU and 2028 US launch window for Pebrilzo
HDFC Sky
·
há 2 dias
Biocon Secures Pebrilzo Launch Dates; Shares Fall 0.94%
TipRanks
·
há 2 dias
Biocon Secures Global Deal with Genentech to Launch Pebrilzo Biosimilar
Perfil
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Sobre Biocon Ltd
CEOShreehas P Tambe
Funcionários16,4 mil
Data de fundação29 de nov. de 1978
SedeBangalore, Karnataka, Índia
Setor-
Sitebiocon.com